南通大学学报（医学版）
南通大學學報（醫學版）
남통대학학보（의학판）
JOURNAL OF NANTONG UNIVERSITY(MEDICAL SCIENCES)
2015年
1期
33-35
,共3页
骨关节炎%复方倍他米松%关节腔灌注
骨關節炎%複方倍他米鬆%關節腔灌註
골관절염%복방배타미송%관절강관주
osteoarthritis%compound betamethasone%intra-articular infusion
目的：探讨复方倍他米松关节腔灌注联合双氯芬酸治疗膝骨关节炎疗效。方法：将我院门诊及病房就诊的确诊膝骨关节炎的60例患者随机分为复方倍他米松治疗组和常规治疗组，复方倍他米松治疗组于基线时予复方倍他米松关节腔灌注治疗1次，同时予双氯芬酸口服治疗，常规治疗组单用双氯芬酸口服治疗。两组患者均予奥美拉唑肠溶胶囊20 mg/d口服，预防消化性溃疡的发生。于基线和4周后观察两组患者的20 m 步行痛、关节触痛、Western Ontario and Macmaster Universities(WOMAC)骨关节炎指数。采用VAS标准评估。结果：常规治疗组20 m步行痛、关节触痛和WOMAC功能在基线时分别为51±15、51±17、618±177；4周后分别为36±1、32±13、392±152；复方倍他米松治疗组20 m步行痛、关节触痛和WOMAC功能在基线时分别为53±13、51±17、620±193，4周后分别为28±12、21±15、336±129；与基线时比较4周后常规治疗组和复方倍他米松治疗组患者的主要疗效指标均较治疗前明显好转(P＜0.05)。4周后复方倍他米松关节腔灌注治疗组的主要疗效指标较常规治疗组改善更明显(P＜0.05)。结论：两组患者临床症状均较治疗前明显改善，联合复方倍他米松关节腔灌注治疗疗效更佳。
目的：探討複方倍他米鬆關節腔灌註聯閤雙氯芬痠治療膝骨關節炎療效。方法：將我院門診及病房就診的確診膝骨關節炎的60例患者隨機分為複方倍他米鬆治療組和常規治療組，複方倍他米鬆治療組于基線時予複方倍他米鬆關節腔灌註治療1次，同時予雙氯芬痠口服治療，常規治療組單用雙氯芬痠口服治療。兩組患者均予奧美拉唑腸溶膠囊20 mg/d口服，預防消化性潰瘍的髮生。于基線和4週後觀察兩組患者的20 m 步行痛、關節觸痛、Western Ontario and Macmaster Universities(WOMAC)骨關節炎指數。採用VAS標準評估。結果：常規治療組20 m步行痛、關節觸痛和WOMAC功能在基線時分彆為51±15、51±17、618±177；4週後分彆為36±1、32±13、392±152；複方倍他米鬆治療組20 m步行痛、關節觸痛和WOMAC功能在基線時分彆為53±13、51±17、620±193，4週後分彆為28±12、21±15、336±129；與基線時比較4週後常規治療組和複方倍他米鬆治療組患者的主要療效指標均較治療前明顯好轉(P＜0.05)。4週後複方倍他米鬆關節腔灌註治療組的主要療效指標較常規治療組改善更明顯(P＜0.05)。結論：兩組患者臨床癥狀均較治療前明顯改善，聯閤複方倍他米鬆關節腔灌註治療療效更佳。
목적：탐토복방배타미송관절강관주연합쌍록분산치료슬골관절염료효。방법：장아원문진급병방취진적학진슬골관절염적60례환자수궤분위복방배타미송치료조화상규치료조，복방배타미송치료조우기선시여복방배타미송관절강관주치료1차，동시여쌍록분산구복치료，상규치료조단용쌍록분산구복치료。량조환자균여오미랍서장용효낭20 mg/d구복，예방소화성궤양적발생。우기선화4주후관찰량조환자적20 m 보행통、관절촉통、Western Ontario and Macmaster Universities(WOMAC)골관절염지수。채용VAS표준평고。결과：상규치료조20 m보행통、관절촉통화WOMAC공능재기선시분별위51±15、51±17、618±177；4주후분별위36±1、32±13、392±152；복방배타미송치료조20 m보행통、관절촉통화WOMAC공능재기선시분별위53±13、51±17、620±193，4주후분별위28±12、21±15、336±129；여기선시비교4주후상규치료조화복방배타미송치료조환자적주요료효지표균교치료전명현호전(P＜0.05)。4주후복방배타미송관절강관주치료조적주요료효지표교상규치료조개선경명현(P＜0.05)。결론：량조환자림상증상균교치료전명현개선，연합복방배타미송관절강관주치료료효경가。
Objective:To detect the effect with articular cavity injection of ompound betamethasone in the patients with knee osteoarthritis. Methods: The 60 patients with knee osteoarthritis from the hospital outpatient and ward in our hospital were collect. The patients were divided into the compound betamethasone treatment group and routine treatment group. The patients of compound betamethasone treatment group were injected with compound betamethasone to articular cavity at baseline. Both of patients were treated with oral diclofenac. All patients were prevented the peptic ulcer with omeprazole enteric capsules. VAS standard was used to evaluate at baseline and 4 weeks with 20 m foot pain, joint tenderness, WOMAC osteoarthritis index. Results: The means of walk 20 m degree of pain, joint tenderness, WOMAC method were 53±13,51±17,620±193 in <br> the patients of routine treatment group at baseline, and they were 36±1,32±13,392±152 after 4 weeks. The means of walk 20 m degree of pain, joint tenderness, WOMAC method (VAS) were 53 ±13,51 ±17,620 ±193 in the patients of compound betamethasone treatment group at baseline,and they were 28±12,21±15,336±129 after 4 weeks. Compared with the baseline the means of walk 20 m degree of pain, joint tenderness, WOMAC method (VAS) had improved significantly(P<0.05) in all patients. Compared with the routine treatment group, the 20 m walking degree of pain, the joint tenderness, WOMAC (VAS) were improved significantly(P<0.05) in the compound betamethasone treatment group. Conclusion: The articular cavity injection of ompound betamethasone combined diclofenac is an effective method for trentment of knee osteoarthritis .
